Plain-English translation of NCT05642572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing combined with —either alone or with an additional drug called —for people with advanced lung cancer that has specific genetic changes (EGFR mutations and MET amplification) and has stopped responding to treatment. The study will compare whether adding to the two-medication combination helps people live longer without their cancer growing.
When lung cancer develops EGFR and MET gene changes, it can become resistant to standard treatments like . This medication combination is designed to target both of these genetic changes at once, and researchers want to know if adding a third drug improves results for patients whose cancer is no longer responding to current therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either two or three daily medications by mouth. You will have regular visits with your cancer doctor to check how well the treatment is working, including CT scans or MRI scans of your chest and brain every few weeks. You will also have blood samples collected before treatment starts, during your first month, and at later checkpoints to help researchers understand how the treatment is affecting your cancer at the genetic level.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States